Human cytolytic fusion proteins

US10246500B2 · kind B2 · utility

Assignee

• UNIVERSITY OF CAPE TOWN · ZA

Inventors

• Stefan Barth · Jena, DE
• Thomas Nachreiner · Jülich, DE
• Christian Cremer · Aachen, DE

Key dates

• Filing date: Jun 15, 2015
• Grant date: Apr 2, 2019
• Expiry date: Jun 15, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/74
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The technology provided herein relates to novel human cytolytic fusion proteins (hCFPs) suitable to induce apoptosis in human cells comprising a target cell-specific binding component and a human effector domain, wherein the binding component comprises an antibody or an antibody fragment with an antigen-binding site for binding to the cellular surface receptor CD64 and the effector domain comprises a variant of wild type human angiogenin (Ang) or a functional fragment thereof; to nucleic acid molecules encoding said recombinant hCFPs, vectors and host cells containing said nucleic acids and methods for preparation and producing these hCFPs.